CN101618164B - Pharmaceutical composition for curing rheumatoid arthritis - Google Patents
Pharmaceutical composition for curing rheumatoid arthritis Download PDFInfo
- Publication number
- CN101618164B CN101618164B CN2009100673195A CN200910067319A CN101618164B CN 101618164 B CN101618164 B CN 101618164B CN 2009100673195 A CN2009100673195 A CN 2009100673195A CN 200910067319 A CN200910067319 A CN 200910067319A CN 101618164 B CN101618164 B CN 101618164B
- Authority
- CN
- China
- Prior art keywords
- rat
- group
- model
- adds
- take
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition for curing rheumatoid arthritis, belonging to traditional Chinese medicines. The pharmaceutical composition comprises the following active materials in percentage by weight: 14-30 beta-eucalyptol, 12-30 inocosterone, 30-50 phellodendron total alkaloid and 30-50 coix seed alcohol extract, is used for curing symptoms, such as the damp invasion of lower energizer, foot and knee inflammation, muscle and joint pain, and the like and has the actions of clearing heat and promoting diuresis.
Description
Technical field
The invention belongs to Chinese medicine, refer in particular to the pharmaceutical composition that is used to treat rheumatoid arthritis.
Background technology
Rheumatoid arthritis is to be master's person property disease with joint and joint surrounding tissue nonsuppurative inflammation, often accompanies disease symptoms outside the joint, so claim rheumatoid disease.Articular cavity synovial membrane inflammation, sepage, cell proliferation, granuloma form, cartilage and bone destruction, last ankylosis and dysfunction.The little joint of many infringements like hands, foot and carpal joint etc., often is a symmetry, is chronic process, and temporary alleviation can be arranged, because the multisystem infringement can be found autoantibody, so think that primary disease is self property disease in the serum.Motherland's medical science is thought the dialectical rheumatism pyretic arthralgia that should be of rheumatoid arthritis, fights mutually for damp and hot, receives ailment said due to cold or exposure outward, or the card due to the rheumatism heat-transformation.Primary disease inside and outside branch arranged, exogenous damp is often hindered earlier in down, many because have a humid climate, paddle drench with rain, due to the external damp invasion and attack human body such as place, residence humidity.Endogenous dampness is a pathological product, is again paathogenic factor, and endogenous dampness is many by dysfunction of the spleen in transportation, and water is wet to be stopped gathering and give birth to.Though it is different that endogenous dampness and exogenous damp have, and in pathogenic process, often influences each other again.Taste are violated in the exogenous damp morbidity more, cause dysfunction of the spleen in transportation, and are wet from interior life; And dysfunction of the spleen in transportation causes the invasion and attack of exogenous damp again easily.It is wet in treatment, should to pay attention to spleen invigorating fortune, benefiting QI and nourishing blood and reinforcing body resistance.
At present the Drug therapy of rheumatoid arthritis is used the more of antibiotic and chemicals; But because of problems such as drug resistance and toxic and side effects are difficult to treatment; Especially really effectively disease controlling development, the desirable medicine that toxic and side effects is little, the minimizing disease recurs still remain to be developed.Because of rheumatoid arthritis serious harm human health, be clinical frequently-occurring disease, difficult disease.According to statistics, its sickness rate is about 1%～2% abroad, and indivedual areas are up to 5%, at the sickness rate of China various places difference slightly, average out to 0.4%.Calculate with this sickness rate, China patient sum is up to 400～5,000,000.Report is arranged, and 2 years disability rates of patient with rheumatoid arthritis of diagnosis and treatment in time do not reach 50%, three year disability rate and reach 70%, compare with the age cohorts, and patient's life-span on average shortens 10～15 years, and in recent years should disease in rising trend.Its characteristics of incidence is to show effect repeatedly, and the state of an illness is touching, and higher disability rate is arranged.Need curative effect certain for this reason, have no side effect, can prevent recurrence, but and the medicine taken of longer-term limit.
Summary of the invention
The present invention provides a kind of pharmaceutical composition that is used to treat rheumatoid arthritis, has the effect of clearing away heat-damp and promoting diuresis, is used to treat damp invasion of lower energizer, and sufficient knee joint is red and swollen, bones and muscles pain.The technical scheme that the present invention takes is: include the active substance by following weight fraction ratio:
14～30 parts of sagittols, 12～30 parts of inokosterone, 30～50 parts of Cortex Phellodendri total alkaloids, 30～50 parts of Semen Coicis ethanol extract.
Be preferably:
22 parts of sagittols, 21 parts of inokosterone, 40 parts of Cortex Phellodendri total alkaloids, 40 parts of Semen Coicis ethanol extract.
Above-mentioned various extracts among the present invention can be preferably through method for distilling acquisition arbitrarily in the prior art:
Sagittol: it is an amount of to take by weighing raw material, with distilled water reflux, extract, 1-3 time, adds 7-15 times of distilled water at every turn and boils filtration in 1-3 hour, and merging filtrate concentrates.
Inokosterone: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 6-17 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
Cortex Phellodendri total alkaloids: it is an amount of to take by weighing raw material, adds 6-18 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filters, and merging filtrate concentrates.
The Semen Coicis ethanol extract: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filters, and merging filtrate concentrates.
The present invention can be mixed with medicament with one or more pharmaceutically acceptable carriers or adjuvant.
Above-mentioned pharmaceutically acceptable carrier is meant pharmaceutical carrier or the adjuvant that pharmaceutical field is conventional, for example: diluent, excipient and water etc., filler such as starch, dextrin, sucrose, mannitol, lactose, microcrystalline Cellulose etc.; Binding agent such as cellulose derivative, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerol: disintegrating agent such as methyl starch sodium, hyprolose, cross-linked carboxymethyl cellulose, agar, calcium carbonate and sodium bicarbonate; Absorption enhancer such as quaternary ammonium compound; Surfactant such as hexadecanol, Tween 80, sodium lauryl sulphate; Alms bowl such as Kaolin and soap clay are carried in absorption; Lubricant such as Pulvis Talci, calcium stearate and magnesium, micropowder silica gel and Polyethylene Glycol etc.In medicament, can also contain other adjuvant such as flavouring agent, sweeting agent etc. in addition.
But the mode of medicament administered through oral, rectum or parenteral that the present invention processes is applied to the patient.Be used for when oral, can be made into conventional solid preparation such as tablet, capsule, powder, granule etc., process other liquid preparation of liquid preparation such as water or oil-suspending agent such as syrup, mixture, elixir etc.; When being used for parenteral, can be made into solution, powder pin, water or the oiliness suspending agent etc. of injection.The preferred form of the present invention is oral liquid, tablet, coated tablet, capsule, granule.
The present invention is used to treat damp invasion of lower energizer, and sufficient knee joint is red and swollen, and diseases such as bones and muscles pain have the effect of clearing away heat-damp and promoting diuresis.The amount of application of the present invention and medicament thereof can be according to variations such as the type of route of administration, patient age, body weight, the disease of being treated and the order of severity, 6g of oral dose, twice on the one.
The specific embodiment
Come further checking the present invention through Pharmacodynamic test of active extract below.
Experimentation
One, experiment material
(1) laboratory animal
40 of healthy wistar rats, male, body weight 180 ± 20g, Jilin University's Experimental Animal Center, sub-cage rearing, 18 ± 2 ℃ of room temperatures, relative humidity 45%～50%, air is fresh, and the well-ventilated freely ingests, drinks water.
(2) experiment medicine and preparation
1, medicine of the present invention hereinafter to be referred as SIMIAO WAN, is provided by the purple prosperous Pharmaceutical in Jilin.SIMIAO WAN is ground into fine powder, take by weighing and put into mortar in right amount, carefully grind the back and be mixed with desired concn with distilled water, 4 ℃ of preservations are heated before the use to 37 ℃.According to experimental rat and people's the every 100g body weight of body surface area proportionality coefficient conversion rat administration 1.0ml/d, dosage is 4.32g/kg.
2. Glucosidorum Tripterygll Totorum: specification is the 30mg/ sheet, and ShangHai Fudan Fuhua Pharmaceutical Co., Ltd produces.With above-mentioned Glucosidorum Tripterygll Totorum, add distilled water after grinding to form fine powder, be configured to desired concn.Body surface area proportionality coefficient according to experimental rat and people converts, the every 100g body weight of rat administration 1.0ml/d, and dosage is 5.4mg/kg.
Two, experimental technique
(1) modeling method
The model preparation of rat assist agent arthritis (AA): face with preceding and take out Freund's complete adjuvant (CFA), fully vibration, mixing from refrigerator.Behind the rat routine disinfection that its right hind is stretching, open up the middle part intradermal injection with the 1ml syringe needle in foot, every rat injection 0.1mlCFA.
(2) animal divides into groups and the administration situation
Group technology: 40 of Wistar male rats are divided into 4 groups at random by the body weight size, 10 every group, are made as blank, matched group, model group, Radix Tripterygii Wilfordii group, SIMIAO WAN group.Wherein model group, Radix Tripterygii Wilfordii group, SIMIAO WAN group rat only give Freund's complete adjuvant by 0.1ml/ and are injected in the right back foot pad of rat.Medication: test 8:00 gastric infusion morning the 8th day every day, once a day, gastric infusion is 21 days continuously, behind last administration 2h, rat is carried out handled.
(3) observation item and method
1. observation item
1.1 the experiments of measuring 1d of body weight weighs, later every 7d weighs once.
1.2 the volumetrical variation of the sufficient sole of the foot
Test 1d, make mark and stretching with marking pen around the hot-tempered joint of rat hind leg, put into sufficient volumetric measurement instrument apparatus pipe, make sufficient labelling equal, to measure every Mus metapedes volume and record when not injecting CFA with its scale.From testing 8d, the next day survey left back whole sole of the foot volume of rat secondary side and record, and calculate swelling degree (ml) for before and after the adjuvant difference of volume according to the left back whole sole of the foot.Observe 21d continuously.
1.3 the calculating of arthritis index (A1)
Cause scorching back 7d and begin observation and record whole body arthropathy degree, every 4d 1 time.The whole body pathological changes is by 5 grades of point system evaluations, according to the lesion degree scores accumulated of all the other 3 limbs of injection adjuvant not, calculates A1.0 minute: do not have red and swollen; 1 minute: the little toe redness and swelling of joints; 2 minutes: toe joint and pedal swelling; 3 minutes: the sufficient pawl swelling below the ankle joint; 4 minutes: comprise the whole sufficient pawl swelling of ankle joint.Get up the score accumulation in each joint, be the A1 of every rat.
1.4 the anti-pain test of pressure
Test 1d and test the anti-pain value of pressure that 28d observes rat secondary side left side foot respectively; Concrete grammar is following: measure with XZC-3T type new lever type digital display tenderness appearance, the gravity block above the shift lever at first, it is placed fulcrum place after; Balancing weight on the adjustment motor plate; Make the pressure display value for " 0000 ", the left side Mus pawl with experimental rat is placed on the pressure platform then, and the cone segments that is about 1mm with the tip is aimed at the same position (joint Lian Chu is stamped on the instep) of right hot-tempered joint tissue; Pin " startup " round button switch; Cone segments will vertically slowly evenly press down, and the numerical value when react with the rats withdraw lower limb this moment is the pressure numerical value of anti-the pain, and the rat pressure numerical value of anti-pain of surveying can show at computer screen automatically.METHOD FOR CONTINUOUS DETERMINATION 3 times, each 5min at interval gets its average as the anti-pain value of pressure.
1.5 animal state observation
Comprise hair color, glossiness and active situation.
2. sample disposal and index detection method
2.1 thymus and spleen weight index
Claim rat body weight, and get animal thymus, spleen, weigh.Calculate thymus and spleen weight index according to rat chest gland weight/rat body weight * 100%, Rats Spleen weight/rat body weight * 100%.
2.2 interleukin-1 ' beta ' is measured
Test 2h after the administration of 29d last, make a collection of specimens.Pluck eyeball and get blood 2ml, leave standstill 30min after, 4 ℃ of centrifugal 15min of 3500rpm, separation of serum is put in the refrigerator for putting and is exempted from index and detect.The interleukin-1 ' beta ' radiometric analysis that using the Beijing North biotechnology research is provided is measured box and is measured the rat blood serum interleukin-1 ' beta ', and experiment by specification step is carried out.
2.3 tumor necrosis factor (TNF) is measured
Test 2h after the administration of 29d last, make a collection of specimens.Pluck eyeball and get blood 2ml, leave standstill 30min after, 4 ℃ of centrifugal 15min of 3500rpm, separation of serum is put in the refrigerator for putting and is exempted from index and detect.Use PLA General Hospital Science and Technology Development Center and put the tumor necrosis factor of exempting to be provided and put and exempt from medicine box and measure the rat blood serum tumor necrosis factor, experiment by specification step is carried out.
2.4 the erythrocyte immune adhesion function is measured
Erythrocyte C
3bReceptor garland (RBCC
3bR) experimental technique: get rat fresh venous (anticoagulant heparin) 50 microlitres and drip in normal saline 3ml, wash centrifugal 2 times, 200 rev/mins, 5 minutes, and be mixed with 1.25 * 10 with normal saline
10The red cell suspension of/L is drawn red cell suspension and C
3bSensitization yeast suspension ((1 * 10
11/ L) each 50 microlitre, in abundant mixing in vitro, 37 ℃ of water-baths were hatched 30 minutes, and it is fixing to add 1 of 0.25% glutaraldehyde again.Mixing, smear wait to do the back Wright's staining, and wet sheet is observed.200 erythrocyte of counting under high power lens, 2 positive garland cells of above yeast person of all combinations are calculated the rosette formation cell percentage rate, as erythrocyte C
3bThe index of receptor active.
(4) statistical procedures
Experimental data adopts the SPSS11.0 statistical software to analyze, and the result is expression with
.Average relatively adopts one factor analysis of variance between each group, relatively adopts the q check in twos.
Three, experimental result
(1) to the influence of AA rat model state and body weight
Rat body weight is as a kind of experimental index of routine; Can reflect the safety of medicine; Through the influence that this medicine of body weight increase and decrease reflection is digested and assimilated system to gastrointestinal tract etc., ordinary circumstances such as rat degree of reaction, mobility also can be used as the side reflection of the whole curative effect of medicine simultaneously.In the whole experiment, the blank control group rat is in good condition, hair luster, and weight increase moves freely, and is quick on the draw.The withered original text of model group rat hair, food-intake reduces, and 2 all body weight slightly increase before experiment, and reducing appears in 2 weeks of experiment back.Right back foot of rat and secondary affection redness and swelling of joints obviously also increase the weight of day by day, and the foot pad obviously thickens, and slow movement reacts insensitive, the difficulty of creeping, the movable minimizing.The symptom that SIMIAO WAN group rat is occurred is lighter relatively, and ingests actively, and rat is active, and body weight continues to increase, and fur is smooth glossy, and right back foot and secondary affection redness and swelling of joints are lighter, and reaction is sensitive.Though Radix Tripterygii Wilfordii group rat symptom is lighter, it is less to take food, and body weight gain is slow, and asthenia is not liked activity, the coarse or jaundice of fur, and right back foot and secondary affection redness and swelling of joints are lighter, and reaction is sensitive.Concrete condition such as table 1:
Table 1 is respectively organized the comparison (g)
that rat body weight changes
With blank control group comparison ▲ P＜0.05, ▲ ▲ P＜0.01; Compare ★ P＜0.05, ★ ★ P＜0.01 with model group
Can know that by table 1 each organizes rat at experiment 1d body weight there was no significant difference (P＞0,05).The blank control group rat body weight increases with the experiment process day by day, and the model group rat has downward trend from experiment 15d body weight.Test the 22nd pattern drawing group rat body weight significant difference (P＜0.01) of having compared with blank control group, SIMIAO WAN group and Radix Tripterygii Wilfordii group rat body weight have statistical significance (P＜0.01 or P＜0.05) apparently higher than the model group rat body weight; But Radix Tripterygii Wilfordii group rat body weight increasess slowly than the SIMIAO WAN group, with blank control group significant difference (P＜0.05) is arranged relatively.
(2) influence that AA rat model secondary affection joint is changed:
1. to the influence of AA rat model secondary affection joint cosmetic variation: rat model is behind right back sufficient sole of the foot intradermal injection CFA; The metapedes pawl begins to redden, obviously swelling; Continue after .3 days; Alleviate gradually, right back foot swelling once again in the 8th day, the swelling local skin is congested, red and swollen, thicken, temperature raises, touch tangible avoidance behaviour arranged.
This experimentation is found, causes scorching back 10d secondary affection and engenders.The left back foot of offside begins redness, and beginning mainly shows ankle joint, and involves whole toe gradually, between toe joint and the front foot sole of the foot arthroncus appears, and touch two hot-tempered joints and present withdrawal reflex, activities adverse, pain reflex is obvious.After the treatment of SIMIAO WAN group and Radix Tripterygii Wilfordii group, the arthroncus of rat pathological changes all has disappearing in various degree, shows that it all can alleviate the inflammatory reaction in model mouse pathological changes joint.
2. AA rat model secondary foot is opened up the influence that the swelling degree changes:
The comparison of table 2 pair AA rat secondary swelling degree of the paw
Compare with blank control group
▲ ▲P＜0.01; Compare with the model ancestral
★P＜0.05,
★ ★P＜0.01
Swelling degree of the paw is the outside objective indicator of reaction AA model hind leg inflammation light and heavy degree.Can know by table 2; Each organize rat cause scorching before and cause the left pedal swelling there was no significant difference (P＞0.05) of scorching back 8d; Cause scorching back 10d and begin, modeling is respectively organized rat and the Secondary cases sufficient pawl swelling in a left side, the 14d after causing inflammation are occurred; Model group rat paw edema degree and blank control group relatively have significant difference (P＜0.01), and SIMIAO WAN group, Radix Tripterygii Wilfordii group rat and model group relatively have significant difference (P＜0.05).Respectively organize the sufficient pawl swelling in a left side of rat Secondary cases about scorching back 20d and peak causing.The effect of the inhibition model mouse secondary sufficient pawl swelling in a left side is in various degree organized, all had to SIMIAO WAN group, Radix Tripterygii Wilfordii, with the poor opposite sex of model group remarkable (P＜0.01).After causing scorching back 28d, better therapeutic effect is organized, still had to SIMIAO WAN group, Radix Tripterygii Wilfordii, with the poor opposite sex of model group remarkable (P＜0.01).Explain that two groups of medicines all can obviously reduce the pedal swelling of AA rat model.
3. the influence that AA rat model arthritis index is changed
Table 3 AA rat joint scoring
Compare with the model ancestral
▲P＜0.05,
▲ ▲P＜0.01
Can know by table 3, behind the model copy 10,14d respectively organizes rat and the poor opposite sex of model group AI not significantly (P＞0.05).After this model group rat A1 raises gradually, about experiment 18d, peaks.Test 18d and rise, SIMIAO WAN group and Radix Tripterygii Wilfordii group relatively have significant difference (P＜0.01 or P＜0.05) with model group.Above result shows that SIMIAO WAN group, Radix Tripterygii Wilfordii group all have the effect that suppresses model mouse A1 rising in various degree, and each medicine all can suppress the arthropathy of AA model mouse secondary side limbs.
4. to the influence of the anti-pain value of AA rat model pressure
Table 4 is respectively organized the comparison (g)
of AA rat pressure tolerance value
Compare with blank control group
▲ ▲Compare with model group p＜0.01
★P＜0.05,
★ ★P＜0.01
This experiment is worth with the anti-pain of the pressure of local organization passes judgment on the SIMIAO WAN analgesic effect.Test 1d and respectively organize the anti-pain value of the pressure there was no significant difference of rat.Test the anti-pain value of 28d model group rat pressure and be starkly lower than blank control group, significant difference (P＜0.01) is relatively arranged, the existence of the quick state of AA rat pain is described with blank control group.After the AA rat was treated through each treatment group, the anti-pain value of pressure obviously raise.Wherein SIMIAO WAN group and model group, relatively significant difference (P＜0.05) arranged, the Radix Tripterygii Wilfordii group relatively has significant difference (P＜0.05) with model group.Above presentation of results SIMIAO WAN group has preferable therapeutic effect to the analgesic effect of the AA rat that is in pathological state.
5. to the influence of AA rat model immune organ
Table 5 is respectively organized the comparison
of AA rat chest gland and spleen weight
Compare with blank control group
▲ ▲Compare with model group p＜0.01
★ ★P＜0.01
The SIMIAO WAN group has the effect that increases AA rat chest gland ponderal index, with model group significant difference (P＜0.01) is arranged relatively.Relatively thymus index is close with the model group rat for the Radix Tripterygii Wilfordii group, and the two is not statistically significant (P＞0.05) relatively.
Perusal model group Rats Spleen obviously increases, and with surrounding tissue adhesion is arranged.AA model group Rats Spleen ponderal index obviously increases than the blank control group rat, and statistical significance (P＜0.01) is arranged.The SIMIAO WAN group has the effect that reduces AA Rats Spleen ponderal index, with model group significant difference (P＜0.01) is arranged relatively.The Radix Tripterygii Wilfordii group also can reduce AA Rats Spleen index, is lower than normally but also make, and the trend that causes the Rats Spleen atrophy is arranged.Above results suggest model group rat immunity dysfunction.The SIMIAO WAN group can effectively be regulated the immunologic function of AA rat, increases the thymic weight index, reduces the spleen weight index, can improve immunologic derangement.
6. to AA rat model serum il-1 β, the influence of TNF-α
Table 6 is respectively organized AA rat 1L-1 β, the comparison of TNF-α
Compare with blank control group
▲ ▲Compare with model group P＜0.01
★ ★P＜0.01
Can know that by table 6 model group rat blood serum IL-1 β, TNF-α and blank control group is apparent in view increases have statistical significance (P＜0.01), explain that model group rat inflammatory reaction is obvious.SIMIAO WAN group, Radix Tripterygii Wilfordii group all can be reduced IL-1 β in the AA rat blood serum, and the TNF-alpha content with the poor opposite sex of model group remarkable (P＜0.01), explains that SIMIAO WAN group, Radix Tripterygii Wilfordii group have the effect that reduces pro-inflammatory cytokine.
7. to the influence of AA rat model erythrocyte immune adhesion function
Table 7 is respectively organized AA rat RBC-C
3bThe comparison of R
Compare with blank control group
▲ ▲Compare with model group P＜0.01
★ ★P＜0.01
Can find out model group AA rat RBC-C by table 7
3bThe receptor rosette rate is compared with blank control group and is obviously reduced, and statistical significance (P＜0.01) is arranged, and explains that the model group rat erythrocyte immune adhesion function occurred and descended, and hints model duplicates successfully.The Radix Tripterygii Wilfordii group compares there was no significant difference (P＞0.05) with model group, SIMIAO WAN group treatment back RBC-C
3bThe receptor rosette rate obviously improves, with the poor opposite sex of model group remarkable (P＜0.01).Above result shows that the SIMIAO WAN group can strengthen the ability that erythrocyte carries immune complex, protection erythrocyte immune adhesion function.
More than test shows that 1. SIMIAO WANs can obviously reduce AA rat swollen joint expansibility, arthritis index; Can obviously improve the anti-pain value of rat pressure; Enhancing is to the protective effect of thymus, spleen immune organ.Can find out that from pharmacodynamic experiment SIMIAO WAN has many-sided effect such as antiinflammatory, analgesia and immunomodulating.2. SIMIAO WAN can be reduced the level of serum TNF-α and IL-1 β, and appropriateness raises erythrocyte immune adhesion molecule C in the serum
3bExpression, accomplish the anti inflammatory immunity regulating action through regulation and control related inflammatory cytokine, erythrocyte immune adhesion function.
Embodiment 1
Sagittol 14g, inokosterone 12g, Cortex Phellodendri total alkaloids 30g, Semen Coicis ethanol extract 30g.
Each extract is mixed, add the conventional adjuvant of preparation tablet, tabletting is processed tablet.
Above-mentioned various extracts among the present invention can be preferably through method for distilling acquisition arbitrarily in the prior art:
Sagittol: it is an amount of to take by weighing raw material, with distilled water reflux, extract, 1-3 time, adds 7-15 times of distilled water at every turn and boils filtration in 1-3 hour, and merging filtrate concentrates.
Inokosterone: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 6-17 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
Cortex Phellodendri total alkaloids: it is an amount of to take by weighing raw material, adds 6-18 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filters, and merging filtrate concentrates.
The Semen Coicis ethanol extract: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filters, and merging filtrate concentrates.
Embodiment 2
Sagittol 22g, inokosterone 21g, Cortex Phellodendri total alkaloids 40g, Semen Coicis ethanol extract 40g.
Add the conventional adjuvant 477g of preparation pill, process 100 balls, every ball 6g.
Embodiment 3
Sagittol 30g, inokosterone 30g, Cortex Phellodendri total alkaloids～50g, Semen Coicis ethanol extract 50g.
The conventional adjuvant that adds the preparation granule is granulated.
Claims (1)
1. a pharmaceutical composition that is used to treat rheumatoid arthritis is characterized in that, is made up of the active substance of following ratio of weight and number: 22 parts of sagittols, 21 parts of inokosterone, 40 parts of Cortex Phellodendri total alkaloids, 40 parts of Semen Coicis ethanol extract; Sagittol prepares as follows: it is an amount of to take by weighing raw material, with distilled water reflux, extract, 1-3 time, adds 7-15 times of distilled water at every turn and boils filtration in 1-3 hour, and merging filtrate concentrates; Inokosterone prepares as follows: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 6-17 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated; Cortex Phellodendri total alkaloids prepares as follows: it is an amount of to take by weighing raw material, adds 6-18 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filters, and merging filtrate concentrates; The Semen Coicis ethanol extract prepares as follows: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filters, and merging filtrate concentrates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100673195A CN101618164B (en) | 2009-07-17 | 2009-07-17 | Pharmaceutical composition for curing rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100673195A CN101618164B (en) | 2009-07-17 | 2009-07-17 | Pharmaceutical composition for curing rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101618164A CN101618164A (en) | 2010-01-06 |
| CN101618164B true CN101618164B (en) | 2012-01-04 |
Family
ID=41511692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100673195A Active CN101618164B (en) | 2009-07-17 | 2009-07-17 | Pharmaceutical composition for curing rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101618164B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111991525B (en) * | 2020-09-02 | 2022-05-03 | 中国药科大学 | Effective component group of Simiao pills and preparation method and application thereof |
| CN114129675B (en) * | 2021-12-29 | 2023-05-09 | 中国药科大学 | Traditional Chinese medicine composition and application thereof |
-
2009
- 2009-07-17 CN CN2009100673195A patent/CN101618164B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101618164A (en) | 2010-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101773551B (en) | External-use medicine composition of traditional Mongolian medicine for curing soft tissue injury | |
| CN101919913B (en) | Composition with effect of treating rheumatoid arthritis | |
| CN103405487B (en) | Chinese medicine compound effective part with effect of treating arthritis | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN101926815B (en) | Paeoniflorin and glycyrrhetinic acid composition and preparation method and application thereof | |
| CN101618164B (en) | Pharmaceutical composition for curing rheumatoid arthritis | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN103446577A (en) | Medicine composition for preventing and treating arthritis and application thereof | |
| CN105233150A (en) | Traditional Chinese medicine composition and application thereof | |
| CN102309705B (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN104352633B (en) | A kind of preparation method of pharmaceutical composition that treating osteoarthropathy | |
| CN104435314B (en) | A kind of pharmaceutical composition for treating osteoarthropathy and its application | |
| CN102579947B (en) | Chinese medicinal composition and preparation method thereof | |
| CN102178759A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method of composition | |
| CN101647855B (en) | Traditional Chinese medicine preparation for treating diabetic neuropathy and preparation method thereof | |
| CN102228512B (en) | Medicine for treating rheumatoid arthritis and preparation method thereof | |
| CN104825922A (en) | Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition | |
| CN106421523B (en) | A kind of Chinese medicine compound prescription for treating gout | |
| CN113633712B (en) | Traditional Chinese medicine composition for treating gout and oral preparation based on traditional Chinese medicine composition | |
| CN114869956B (en) | Pharmaceutical composition for treating post-stroke dyskinesia, and preparation method and application thereof | |
| CN107281459A (en) | It is a kind of to treat Chinese medicine composition of rheumatoid arthritis and preparation method thereof | |
| CN101897752B (en) | Chinese medicinal composition and preparation method thereof | |
| CN107303330A (en) | One kind prevents antipodagric Chinese medicine composition and preparation method and application | |
| CN102018849A (en) | Traditional Chinese medicine composition for preventing irregular menstruation and preparation method thereof | |
| CN1872165A (en) | A medicine combination, preparation method and method for controlling quality |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Pharmaceutical composition for curing rheumatoid arthritis Effective date of registration: 20190318 Granted publication date: 20120104 Pledgee: Jilin rural commercial bank and Limited by Share Ltd Pledgor: Jilin Zixin Pharmaceutical Co., Ltd. Registration number: 2019220000006 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20210929 Granted publication date: 20120104 |
|
| PP01 | Preservation of patent right |